Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939372 | 0.90 | PKM (0.36) | NR1H2PKMGPR119PTPN2PTPN1 | |
| SCHEMBL4941222 | 0.87 | NR1H2 (0.43) | NR1H2PKMGPR119PTPN2PTPN1 | |
| SCHEMBL3085985 | 0.82 | CHRM5 (0.41) | NR1H2PKMHDAC1HDAC6 | |
| SCHEMBL4937394 | 0.82 | REN (0.46) | — | |
| SCHEMBL4941012 | 0.77 | NR1H2 (0.43) | NR1H2PKMGPR119RORCHDAC1 | |
| SCHEMBL3096155 | 0.75 | CHRM5 (0.39) | NR1H2GPR119HDAC1HDAC6 | |
| SCHEMBL4930538 | 0.73 | REN (0.45) | RORC | |
| SCHEMBL4932897 | 0.73 | REN (0.46) | — | |
| SCHEMBL3044833 | 0.69 | CHRM5 (0.43) | NR1H2PKMGPR119 | |
| SCHEMBL4934280 | 0.69 | NR1H2 (0.41) | NR1H2GPR119RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | REN, AGTR1, CBR1 | NR1H2 797/4885PKM 390/4885GPR119 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.